Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Afatinib |
| Trade Name | Gilotrif |
| Synonyms | BIBW 2992|Giotrif |
| Drug Descriptions |
Gilotrif (afatinib) is a second-generation pan-Egfr inhibitor with activity against EGFR T790M and EGFR exon 19 and 21 deletions, and also inhibits ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4) (PMID: 24435321, PMID: 25505694). Gilotrif (afatinib) is FDA approved for use in non-small cell lung cancer patients harboring non-resistant EGFR mutations, including exon 19 deletions, L858R, S768I, G719X, and L861Q, and for patients with metastatic squamous NSCLC (FDA.gov). |
| DrugClasses | EGFR Inhibitor (Pan) 63 EGFR Inhibitor 2nd gen 5 HER inhibitor (Pan) 6 |
| CAS Registry Number | 850140-72-6 |
| NCIT ID | C66940 |